These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 35126303)

  • 1. The Alteration of Circulating Lymphocyte Subsets During Tacrolimus Therapy in Neuromyelitis Optica Spectrum Disorder and Its Correlation With Clinical Outcomes.
    Wang L; Huang W; ZhangBao J; Chang X; Tan H; Zhou L; Lu C; Wang M; Lu J; Zhao C; Quan C
    Front Neurol; 2021; 12():816721. PubMed ID: 35126303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating regulatory B cell subsets in patients with neuromyelitis optica spectrum disorders.
    Han J; Sun L; Wang Z; Fan X; Wang L; Song YY; Zhu J; Jin T
    Neurol Sci; 2017 Jul; 38(7):1205-1212. PubMed ID: 28389940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tacrolimus is effective for neuromyelitis optica spectrum disorders with or without anti-AQP4 antibody.
    Kojima M; Oji S; Tanaka S; Izaki S; Hashimoto B; Fukaura H; Nomura K
    Mult Scler Relat Disord; 2020 Apr; 39():101907. PubMed ID: 31931404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The imbalance between regulatory and memory B cells accompanied by an increased number of circulating T-follicular helper cells in MOG-antibody-associated demyelination.
    Li X; Wang L; Zhou L; ZhangBao J; Miao MZ; Lu C; Lu J; Quan C
    Mult Scler Relat Disord; 2019 Nov; 36():101397. PubMed ID: 31546225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose tacrolimus in treating neuromyelitis optica spectrum disorder.
    Wang L; Tan H; Huang W; ZhangBao J; Chang X; Zhou L; Lu C; Wang M; Lu J; Zhao C; Quan C
    Mult Scler Relat Disord; 2021 Feb; 48():102707. PubMed ID: 33383362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peripheral CD19
    Ellrichmann G; Bolz J; Peschke M; Duscha A; Hellwig K; Lee DH; Linker RA; Gold R; Haghikia A
    J Neurol; 2019 Jan; 266(1):57-67. PubMed ID: 30377816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The IL-10-producing regulatory B cells (B10 cells) and regulatory T cell subsets in neuromyelitis optica spectrum disorder.
    Cho EB; Cho HJ; Seok JM; Min JH; Kang ES; Kim BJ
    Neurol Sci; 2018 Mar; 39(3):543-549. PubMed ID: 29349658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional impairment of CD19
    Kim Y; Kim SY; Han SM; Payumo RM; Park K; Kim HE; Kim SH; Hyun JW; Lee E; Kim HJ
    Sci Transl Med; 2021 Dec; 13(624):eabk2132. PubMed ID: 34910550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Late onset neuromyelitis optica spectrum disorder with anti-aquaporin 4 and anti-myelin oligodendrocyte glycoprotein antibodies.
    Wang L; Tan H; Huang W; Chang X; ZhangBao J; Zhou L; Lu C; Wang M; Lu J; Zhao C; Quan C
    Eur J Neurol; 2022 Apr; 29(4):1128-1135. PubMed ID: 34967093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lymphocyte Subsets Are Associated with Disease Status in Neuromyelitis Optica Spectrum Disorders.
    Yang H; Liu W; Wu YF; Zhu DS; Shen XF; Guan YT
    Neuroimmunomodulation; 2022; 29(4):296-305. PubMed ID: 34903694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Condition-dependent generation of aquaporin-4 antibodies from circulating B cells in neuromyelitis optica.
    Wilson R; Makuch M; Kienzler AK; Varley J; Taylor J; Woodhall M; Palace J; Leite MI; Waters P; Irani SR
    Brain; 2018 Apr; 141(4):1063-1074. PubMed ID: 29447335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and immunological differences between MOG associated disease and anti AQP4 antibody-positive neuromyelitis optica spectrum disorders: Blood-brain barrier breakdown and peripheral plasmablasts.
    Tanaka S; Hashimoto B; Izaki S; Oji S; Fukaura H; Nomura K
    Mult Scler Relat Disord; 2020 Jun; 41():102005. PubMed ID: 32114369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impaired regulatory function and enhanced intrathecal activation of B cells in neuromyelitis optica: distinct from multiple sclerosis.
    Quan C; Yu H; Qiao J; Xiao B; Zhao G; Wu Z; Li Z; Lu C
    Mult Scler; 2013 Mar; 19(3):289-98. PubMed ID: 22864301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. B-cell proliferation characteristics and monitoring significance under the modified reduced-dose rituximab regimen for NMOSD: A real-world case series study.
    Cao S; Wang X; Ji X; Tian J; Zhu Y; Wang X; Gu Y; Duan X; Xiao X; Fang Q; Zhang X; Xue Q
    Mult Scler Relat Disord; 2023 Feb; 70():104524. PubMed ID: 36701910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial.
    Nikoo Z; Badihian S; Shaygannejad V; Asgari N; Ashtari F
    J Neurol; 2017 Sep; 264(9):2003-2009. PubMed ID: 28831548
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of effect of empirical attack-preventive immunotherapies in neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis.
    Ma J; Yu H; Wang H; Zhang X; Feng K
    J Neuroimmunol; 2022 Feb; 363():577790. PubMed ID: 34959021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Proportion and significance of CD1d(hi)CD5⁺CD19⁺ regulatory B cell in peripheral blood of patients with neuromyelitis optica].
    Yang F; Huang D; Cheng C; Wu W
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2015 Mar; 31(3):375-8. PubMed ID: 25744844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder.
    Yang Y; Wang CJ; Wang BJ; Zeng ZL; Guo SG
    J Neurol Sci; 2018 Feb; 385():192-197. PubMed ID: 29406904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Age at onset predicts outcome in aquaporin-4-IgG positive neuromyelitis optica spectrum disorder from a United Kingdom population.
    Papathanasiou A; Tanasescu R; Tench CR; Rocha MF; Bose S; Constantinescu CS; Jacob S
    J Neurol Sci; 2021 Dec; 431():120039. PubMed ID: 34715481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The frequencies of peripheral blood CD5
    Khani L; Jazayeri MH; Nedaeinia R; Bozorgmehr M; Nabavi SM; Ferns GA
    Allergy Asthma Clin Immunol; 2022 Jan; 18(1):5. PubMed ID: 35031055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.